Unleashing Joy: Introducing He-Man, Chief Dog Officer at Antheia

He-Man serves as Antheia’s Chief Dog Officer (CDO), where he has worked diligently to make a paw-sitive impact on employee morale, team dynamics, and the company treat budget. In this blog, He-Man shares more about his exciting life at Antheia and his invaluable role in boosting morale. From Humble Biotech Beginnings to Biomanufacturing Brilliance Before […]
The Road to Commercialization

Antheia’s Chief Operations Officer Zack McGahey offers his perspective on the company’s most recent commercial milestone – a successful full-scale fermentation run of its first product at 116,000L.
Introducing Richard Sherwin, Antheia’s SVP of Commercialization

As the newly appointed Senior Vice President of Commercialization, Richard Sherwin is poised to move Antheia into its next phase by building a vibrant commercial market footprint. His collaborative work with Antheia has spanned nearly a year as a fractional, valued member of the team, and as of August 2023, he’s now full time in preparation for what will be a milestone year in Antheia’s history.
Introducing Jordyn Lee, Antheia’s Director of Communications

As the newly minted Director of Communications, Jordyn Lee owns the voice of Antheia and all of the ways the brand shows up, from industry conferences to digital content. With a deep background in technical communications and public relations, she brings a passion for scientific storytelling to the forefront during a landmark year, as Antheia […]
Introducing Yen-Hsiang Wang, Antheia’s VP of Strategy and Partnerships

As the Vice President of Strategy and Partnerships, Yen-Hsiang Wang is the strategic powerhouse behind Antheia, tasked with bringing its technology and pipeline of products from ideation into realization. As a catalyst for the commercial viability of Antheia’s technology into the pharma world, this scientific innovator-turned-business leader combines his deep bench of scientific expertise in […]
Addressing the Drug Shortage Crisis: Transforming Pharma Supply Chains

Drug shortages in the U.S. have become an urgent issue over the last few years. So much so that in 2020, the Administration issued an Executive Order for the U.S. FDA to establish an Essential Medicines List of critical drugs that are deemed medically necessary, with the ultimate goal of identifying ways to protect and […]
The Natural Synergy Between Synthetic Chemistry and Synthetic Biology

At Antheia, we spend a lot of time talking about synthetic biology due to the nature of our work engineering yeast to produce key starting materials (KSMs) and active pharmaceutical ingredients (APIs) for essential medicines. However, synbio’s cousin, the long-established field of synthetic chemistry, plays a vital role. This is the third and final blog […]
Introducing Antheia’s Reinvigorated Brand Identity

Since launching Antheia in 2015, we’ve made tremendous strides toward our mission to transform pharmaceutical supply chains for essential medicines. We’ve strengthened our leadership team with veteran executives across R&D, operations, supply chain, and quality and regulatory, we’ve repeatedly validated our technology at commercially-relevant scales, and we are now actively moving into full-scale production to bring our products to market.
Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines

Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Live at SynBioBeta

Each year, SynBioBeta hosts the The Global Synthetic Biology Conference to showcase the latest cutting-edge developments in biology that are changing how we solve global problems. As a proud sponsor of this year’s event, we look forward to connecting with the synthetic biology community and sharing our progress toward transforming pharmaceutical supply chains.